Analysis of outcomes of 800 patients w/ relapsed or refractory DLBCL, treated w/ commercially available CART cell therapy, supports higher efficacy & toxicity of axicabtagene ciloleucel compared to tisagenlecleucel as the 3rd line treatment. lymphoma
. In the first one, 356 patients treated with CAR T in Germany were considered . After adjusting for six parameters in a Cox model, PFS was significantly longer after axi-cel infusion than after tisa-cel infusion. No significant difference was observed for OS. In the second one, 68 patients from the United States treated with axi-cel were compared to 31 patients treated with tisa-cel, showing higher response rate after axi-cel infusion.
In conclusion, although only a randomized study could allow for an undisputable comparison between the two CAR T products, our study is in favor of a higher efficacy but also a higher toxicity of axi-cel compared to tisa-cel in ≥3rd line of treatment for R/R DLBCL. These results need to be confirmed by other large RWE studies with similar statistical methods to account for imbalance between patient characteristics.
IPTW was used as another statistical approach to allow for outcome comparison between patients treated with axi-cel and patients treated with tisa-cel. In the IPTW method, the weight for each patient is calculated by inverting the probability of receiving the treatment the patient actually receives. PSM and IPTW rely on different statistical matching approaches, provide different information and should be interpreted differently.
Argentina Últimas Noticias, Argentina Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
From the 800 to the Marathon: The Story Behind Tigist Assefa’s Berlin BreakthroughThe 28-year-old is the first woman to break 2:00 in the 800 meters and 2:20 in the marathon.
Leer más »
At WORTHLESSSTUDIOS, ‘1-800 Happy Birthday’ Honors Black and Brown Victims of Police ViolenceArtist Mohammad Gorjestani’s hope for the exhibition, on through January 16, is that it reminds people that every victim had a life before it was stolen.
Leer más »
CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial - Nature MedicineBicistronic CART cells targeting CD19 & CD22 show clinical activity in pediatric & young adult patients w/ B cell acute lymphoblastic leukemia, w/ relapses associated w/ limited CAR T cell persistence. ChildhoodCancerAwarenessMonth NMEDclinical
Leer más »
KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape - Nature MedicineA new dual-chimeric antigen receptor (CAR) system enhances the antitumor activity of CAR natural killer cells and makes them less susceptible to therapeutic resistance in preclinical models. lab_rezvani CARNK therapyresistance
Leer más »